Bicuspid Valve Aortic Regurgitation in a Young Adult: Earlier Repair or Continued Surveillance?
His anatomy still favors a durable valve repair today, but standard surgical thresholds haven't been met yet — a tension between operating while the window is open and waiting for a clearer indication.
D.R., a 26-year-old man, trains for amateur cycling races most weekends and has never had a cardiac symptom in his life — his bicuspid aortic valve was found on an echocardiogram ordered after a routine physical picked up a diastolic murmur, not because anything was bothering him. Over three years of surveillance since, his aortic regurgitation has progressed from moderate to severe, and his most recent echo shows early left ventricular enlargement that sits right at the edge of what most guidelines would call a clear surgical indication, without yet crossing it outright. The thresholds that would settle it are specific: for asymptomatic severe aortic regurgitation, surgery is clearly indicated once the ejection fraction falls to 55% or below, and is reasonable once the left ventricular end-systolic dimension exceeds 50 mm, or 25 mm/m² when indexed to body surface area. His numbers sit just underneath both.
The question in front of his team isn't only whether to operate — it's what kind of operation, and increasingly, when. Aortic valve repair in bicuspid-valve regurgitation, preserving his own leaflets rather than replacing them, avoids the two costs that come with any prosthesis: lifelong anticoagulation with a mechanical valve, or the finite lifespan and eventual reoperation that comes with a bioprosthetic one, both particularly consequential for a man his age with decades of expected life ahead. But repair durability in bicuspid AR is less predictable than in some other regurgitant lesions, and the surgical literature suggests repair outcomes are generally best when performed before significant ventricular remodeling has occurred — which raises a real tension between waiting for a clearer, guideline-anchored indication to operate and potentially operating somewhat earlier, while his anatomy still favors a durable repair, at the cost of intervening before his LV has definitively crossed into surgical territory.
In clinic, at the edge of the threshold
By the numbers alone, he sits right at the edge of a standard surgical threshold rather than clearly past it, and the traditional approach would be to keep watching until he crosses it unambiguously or develops symptoms. But watching has a real cost specific to his case: repair durability in bicuspid AR is generally better when performed before significant ventricular remodeling, and his LV is already showing early change. Waiting for an unambiguous threshold risks watching his anatomy shift out of the window where repair is most likely to hold.
If his valve anatomy weren't favorable for repair to begin with, I wouldn't be raising early surgery at all — a patient heading toward replacement regardless doesn't have the same time-sensitive repair window to protect, and standard watchful waiting would be entirely reasonable.
I want to be careful about treating 'the repair window might close' as equivalent to a guideline indication, though. He is asymptomatic, tolerating serious athletic training without any limitation, and operating on an asymptomatic 26-year-old on the strength of a favorable-anatomy argument rather than a met threshold is a real decision to accept surgical risk earlier than standard practice would ask for. I'd want his surveillance interval shortened rather than jump straight to an earlier-than-standard operation.
I'm not dismissing the repair-durability argument — it's a real consideration. I just think it should sit alongside the standard threshold criteria as one input into his and the surgical team's shared decision, not override them on its own for someone with no symptoms and preserved exercise tolerance.
There isn't a medication that changes the trajectory of bicuspid-valve AR meaningfully — this is fundamentally a surgical timing question, not a pharmacologic one. If he develops hypertension at any point, afterload reduction with an ACE inhibitor or dihydropyridine calcium channel blocker would be reasonable, though I want to be clear that vasodilator therapy hasn't been shown to meaningfully delay the need for surgery in patients who are normotensive to begin with, the way it's sometimes assumed to. I think the actual resolution is giving him the real tradeoff directly rather than the team deciding it for him — he's an informed, engaged patient, and letting him weigh anticoagulation-avoidance and repair durability against his own risk tolerance is the most honest way through this.
Agreed: the tradeoff explained to him directly — earlier anatomy-favorable repair versus continued surveillance to a harder threshold — with a shortened surveillance interval either way, and the decision left with him rather than made on his behalf.
Surgery proceeds while his anatomy is assessed as most favorable for durable repair, accepting surgical risk somewhat ahead of a strict guideline threshold.
Echo monitoring continues every 4 to 6 months, with earlier surgery reconsidered immediately if his LV crosses a clearer threshold or repair favorability appears to be declining.
Whichever he chooses, his cycling and training plans will factor into the timing conversation directly, not as an afterthought.